Gland Pharma Q4 PAT jumps 97% YoY to Rs 367 crore
Mumbai, May 15 -- Revenue from USA aggregated to Rs 980.7 crore (up 25.44% YoY), Europe revenue added up to Rs 381.4 crore (up 36% YoY) and that from Rest of the world was Rs 254.9 crore (up 6% YoY). Sales in Canada, Australia and New Zealand were Rs 58.8 crore (down 2% YoY) and those in India were Rs 67 crore (up 28% YoY).
Profit before tax stood at Rs 505.79 crore in Q4 FY26, up by 75.42% from Rs 288.33 crore recorded in Q4 FY25.
Consolidated EBITDA stood at Rs 513 crore in Q4 March 2026, registering the growth of 48% YoY with EBITDA margin of 29%.
R&D expenses stood at Rs 50.6 crore in Q4 FY26, accounting for 4% of base business revenue, and were primarily directed toward complex product development and filings. During the quarter, ...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.